Skip to main content

Table 1 Pharmacokinetic analysis of ACY-1083

From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment

  ACY-1083 plasma concentration ACY-1083 Brain concentration Brain to plasma ration
Dose (mg/kg) Dose route Sampling
time (hr)
Mean (ng/mL) SD CV (%) Mean (ng/g) SD CV (%) Mean SD CV (%)
5 IP Predose NA NA NA NA NA NA BQL NA NA
   0.08 654.33 58.71 8.97 44.13 11.68 26.46 0.07 0.01 18.72
   0.25 936.00 91.43 9.77 109.50 10.26 9.37 0.12 0.01 4.27
   1 180.00 11.00 6.11 112.33 8.08 7.20 0.63 0.08 13.33
   4 78.30 7.39 9.44 15.17 2.41 15.88 0.20 0.04 22.38
  1. Abbreviations: BQL below the quantifiable limit of 1.00 ng/mL of ACY-1083 in mouse plasma and brain homogenates, CV coefficient of variation, NA not available, SD standard deviation